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Summary. Background: Inter-assay variability is a wellknown problem in antiphospholipid antibody testing, because of the lack of standardization. Inter-laboratory reproducibility for the same assay is similarly important. Objectives: Testing repeatability and reproducibility of HemosIL Ò AcuStar for anticardiolipin (aCL) and antib2-glycoprotein I antibodies (ab2GPI) IgG and IgM. Patients/Methods: In this observational study, out of 420 samples from the thrombophilia centers of Ghent and Geneva, 100 samples were randomly selected and successively analyzed in three centers: Ghent (C1, in duplicate for repeatability evaluation), Geneva (C2) and Frankfurt (C3). Results: Results from 99 samples were available, including 25 from patients with antiphospholipid syndrome (APS) and 74 from non-APS patients. The intra-center repeatability expressed as intraclass correlation coefficient (ICC) was higher than 0.99 for each parameter. Differences between two measurements rarely exceeded 1 U mL À1 for values below 100 U mL À1 , except for ab2GPI IgG, where differences varied from À4 to 4 U mL
À1
. The inter-center ICCs were higher than 0.99, except for aCL IgM (ICC = 0.961). These ICCs remained high even when considering values below 100 U mL À1 (0.943, 0.964
Introduction Anticardiolipin (aCL) and antib2-glycoprotein I antibodies (ab2GPI) are two out of the three laboratory criteria for the classification of antiphospholipid syndrome (APS) (1) . Because clinical features of APS (thrombosis and pregnancy complications) are often related to other underlying factors, the diagnosis of APS relies on the detection of antiphospholipid antibodies (aPL). Therefore, we need reliable tests with good clinical performance and good reproducibility. There is a large variety of solid phase assays available to assess aPL but standardization of assays has still not been achieved (2) (3) (4) . Inter-assay and inter-laboratory variation has been described (5), with several factors contributing to variability in results, including pre-, post-and analytical conditions, calibration and assay-specific issues (6) . Laboratory workers, as well as clinicians, should be aware of this inter-assay variability and consider retesting with another assay if there is a high suspicion of APS but a negative result with the initial assay. Recently, guidelines with recommendations for detection of aCL and ab2GPI antibodies by solid phase assays were published by the Standardization Subcommittee of the International Society of Thrombosis and Haemostasis (SSC-ISTH) to achieve more standardization and harmonization in aPL testing (7) . However, few studies report on inter-laboratory variability within the same assay. Patients who do have the disease, tested for in different laboratories with the same assay, should be identified correctly. Pengo et al. reported on variability among different and within the same commercial aCL and ab2GPI ELISAs (8) . For solid phase aPL assays more and more automated systems have been introduced into the market; those with chemiluminescent technology introduced in 2010 (9) have been widely used ever since (9) (10) (11) (12) (13) (14) (15) . We tested the repeatability of the HemosIL Ò AcuStar system (Instrumentation Laboratory, Bedford, MA, USA) within one center, and the reproducibility between two other centers, in a group of previously diagnosed APS and non-APS patients.
Materials and methods
Four hundred and twenty samples were selected from individuals referred to the thrombophilia centers of Ghent (Center 1, C1) and Geneva (C2) with evidence of APSrelated symptoms (thrombosis or pregnancy morbidity) or referred for autoimmune disease testing with request for aPL testing. This population fulfilled the selection criteria as advised in the guidelines and is representative of our daily practice (16 The final sample collection (n = 99; one sample had not enough plasma volume) included 25 patients with APS, 30 patients with AID, 24 DC and 20 NC. These samples were reanalyzed by three centers (C1, C2, and Frankfurt C3) for aCL and ab2GPI IgG and IgM antibodies by HemosIL Ò AcuStar on citrated plasma (7) . In C1 the reanalysis was performed in duplicate. Ninety-six and 74 out of 99 samples were measured in C2 and C3, respectively, due to lack of sample volume. All centers used their current batch of reagents, which were different for the three centers. Results lower than the locally derived limit of detection (LOD) were replaced by the value of the LOD in order to integrate them into statistical analysis. Samples were stored at À80°C until reanalysis by the three centers (C1-C2-C3), with successive shipments of samples between laboratories performed using dry ice. The samples had a maximum of two freeze/thawing cycles (17) . Results of each lab were compared head to head. For the repeatability analysis (duplicate measurements performed by C1 in two consecutive runs), the reliability was assessed with an intra-class correlation coefficient (ICC) using a one-way ANOVA model (ICC(1,1) of Shrout and Fleiss (18) . Because data were highly skewed and ICC depends on the between-subject variability we also assessed the ICC on values below 100 U mL À1 (arbitrarily chosen). Agreement between replicated measures for values below 100 U mL À1 was assessed using Bland-Altman plots. Calculation of the limits of agreement assumes that the standard deviation of the differences is uniform throughout the range of measurements. Because this hypothesis was violated and no simple data transformation could be found to overcome that problem, we chose to report Bland-Altman plots on original values without estimating limits of agreement. As measurements were missing in some centers because of lack of sample volume, reliability between centers was assessed using a linear mixed effect model. As we aimed to assess the reliability between centers in general, we considered the centers participating in this study as a sample of a population of centers. Thus between-centers reliability was assessed using a two-way random-effects model with a random-effect on subject and a randomeffect on center. Because C2 and C3 did not have any duplicated measures, we arbitrarily chose the first Statistical analyses were performed using R software (Vienna, Austria, URL http://www.R-project.org/).
Results and discussion
Repeatability assessed by intra-center ICC was higher than 0.99 for each of the four parameters ( Table 1 ). The ICC values remained above 0.99 even when focusing on values lower than 100 U mL À1 for each parameter.
Bland-Altman plots (Fig. 1) show that the measurement error increased along with the values. Differences between two measurements rarely exceeded 1 U mL
À1
, except for ab2IgG where differences varied from À4 to 4 U mL À1 .
Out of 99 samples, one sample showed an ab2GPI IgG lower than the cut-off of 17.4 U mL À1 on the first measure (14 U mL À1 , negative), whereas the second measure was higher (18.2 U mL À1 , positive). One other sample
showed an ab2GPI IgM value superior to 12 U mL À1 (12.1 U mL À1 , positive) on the first measure, whereas the second measure was exactly 12 U mL À1 and was therefore classified as 'negative'. When evaluating the between-centers reproducibility by comparing C1 and C2 results, we observed that C2 against the mean value of the two measurements (x-axis) for each aPL parameter (A, aCL IgG; B, aCL IgM; C, ab2GPI IgG; D, ab2GPI IgM). Dotted lines represent the identity line. aCL, anticardiolipin antibodies; ab2GPI, antibeta2-glycoprotein I antibodies. tended to give somewhat higher results for ab2GPI IgG and ab2GPI IgM when values increase (Fig. 2) . When comparing C1 results with C3 results, this phenomenon was even more evident and general to all parameters. The inter-center ICCs (Table 1) were nonetheless high, with values above 0.99, except for aCL IgM, where ICC was 0.961. Inter-center ICCs remained high even when considering values below 100 U mL À1 (0.943, 0.964 and 0.977 for aCL IgG, aCL gM and ab2GPI IgM, respectively), except for ab2GPI IgG, where the ICC fell to 0.652. The lower reproducibility of ab2GPI IgG between centers was mainly due to C3, as the reliability (ICC) between C3 and C1 and between C3 and C2 was 0.427 and 0.519, respectively, whereas it was 0.900 between C1 and C2. BlandAltman plots (Fig. 2) support the idea that C2 results tended to be higher than those in C1 for ab2GPI IgG and to a lesser extent for ab2GPI IgM, when values increase. Similar results were obtained when comparing C1 and C3 (Fig. 2 E-H) . Finally, the measurement error between centers increased throughout the range of measurements; its amplitude varied from one parameter to another (being the lowest for aCL IgM and the highest for ab2GPI IgG) and was globally higher than the intracenter measurement error assessed in C1.
Qualitative comparison between C1 and C2 showed differences in classification of 0-4 samples ( ). C3, compared with C2 and C1, classified 10 and nine additional samples positive for ab2GPI IgG, respectively. The same samples (n = 9) positive in C3 were negative in C1 and C2, illustrating that titers were on average slightly higher in C3. Discrepancies were all in samples with values around the cut-off (between 14.1 U mL À1 and 28.6 U mL
). No discrepancies were observed for ab2GPI IgM.
The inter-center agreement (Table 2) varied between 85% (for ab2GPI IgG C2/C3) and 100% (for ab2GPI IgM C1/C2 and C2/C3, and for aCL IgM C1/C2).
Assay-to-assay variation is a well-known problem and remains a challenge in standardization of solid phase assays for aPL (4) . Because automated systems have more harmonized protocols, less inter-laboratory variability within a system is expected. Results of external quality control schemes show that coefficients of variation between methods are lower for automated systems compared with ELISA (no published results so far). As expected for automated systems, we observed a high repeatability, even in values below 100 U mL À1 . Duplicate testing for aPL used to be recommended to avoid errors mainly due to pipetting techniques. This is mainly true for manual ELISA; the technical progress of new platforms with automated pipetting seems to reduce the need for duplicate testing. All between-run CVs in all centers were below 10%, in accordance with the recommendations (7). However, we observed two measurements for ab2GPI IgG exceeding a difference of 1.74 U mL À1 (10% of the cut-off value). One sample was classified on the first measurement as negative (14 U mL
), whereas on the second measurement it was positive (18.2 U mL
). Reproducibility between centers was good when considering the overall range of titers. However, for values below 100 U mL À1 , the reproducibility between centers was somewhat lower for ab2GPI IgG, with around 10% of discordant results, mainly around the cut-off value. The different batches of reagents used across centers may account for this difference. Our study has some limitations. First, the repeatability evaluation was performed in one center only (C1) because of the limited volume available. Secondly, this study addressed the reproducibility of one single system that cannot be generalized to all automated systems. Thirdly, the limited volume of samples did not allow testing all aliquots in all centers. Finally, and because of the same issue of volume of plasma, the number of centers was limited to three.
In conclusion, in terms of discriminating properties, the HemosIL Ò AcuStar has excellent intra-center repeatability and a good inter-center reproducibility for aCL IgG, aCL IgM and ab2GPI IgM. Based on small differences around the cut-off value and lower inter-center reproducibility, concern may arise over ab2GPI IgG.
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